SER
$1.34
Post-MarketAs of Mar 17, 8:00 PM UTC
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.34
Potential Upside
5%
Whystock Fair Value$1.41
Price
UndervaluedFair ValueOvervalued
Fundamentals
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclini...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$14.45M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.98
Recent News
Fed Politics Weigh on Investor Sentiment, Driving Muted Premarket Action for US Equity Futures
US equity futures were flat ahead of Tuesday's opening bell after President Donald Trump said he was
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as Investors Await Economic Data, Trump Orders to Remove Lisa Cook
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr